23andMe Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 709

Employees

  • Stock Symbol
  • MEHCQ

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.27
  • (As of Tuesday Closing)

23andMe General Information

Description

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Contact Information

Website
www.23andme.com
Formerly Known As
Bleecker Street Acquisition
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 223 North Mathilda Avenue
  • Sunnyvale, CA 94086
  • United States
+1 (800)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Devices and Supplies
Biotechnology
Stock Exchange
PINX
Vertical(s)
LOHAS & Wellness, Digital Health, Life Sciences
Corporate Office
  • 223 North Mathilda Avenue
  • Sunnyvale, CA 94086
  • United States
+1 (800)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

23andMe Stock Performance

As of 22-Apr-2025, 23andMe’s stock price is $1.27. Its current market cap is $34.1M with 26.8M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.27 $1.28 $0.48 - $12.76 $34.1M 26.8M 3.98M -$15.70

23andMe Financials Summary

As of 31-Dec-2024, 23andMe has a trailing 12-month revenue of $209M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 29,970 93,316 689,327 1,214,005
Revenue 208,775 219,638 299,489 271,893
EBITDA (418,118) (657,662) (292,004) (197,547)
Net Income (390,372) (666,704) (311,656) (217,490)
Total Assets 277,422 395,167 942,598 1,152,068
Total Debt 60,544 76,515 85,304 86,308
Public Fundamental Data provided by Morningstar, Inc. disclaimer

23andMe Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consu
Laboratory Services (Healthcare)
Sunnyvale, CA
709 As of 2025

Hilden, Germany
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

23andMe Competitors (9)

One of 23andMe’s 9 competitors is Qiagen, a Formerly VC-backed company based in Hilden, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qiagen Formerly VC-backed Hilden, Germany
Illumina Formerly VC-backed San Diego, CA
Personalis Formerly VC-backed Fremont, CA
Promethease Corporate Backed or Acquired
OmeCare Formerly VC-backed San Diego, CA
You’re viewing 5 of 9 competitors. Get the full list »

23andMe Patents

  • 381

    Total Documents Applications and Grants

  • Total Patents Families

  • 247

    Granted

  • 56

    Pending

  • Expiring in next 12 mo

23andMe Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240428884-A1 Analyzing and merging data from genome-wide association studies Pending 22-Jun-2023
US-20240120028-A1 Learning architecture and pipelines for granular determination of genetic ancestry Pending 05-Oct-2022
US-20230348604-A1 Antigen binding proteins Active 29-Apr-2022
US-12060426-B2 Anti-ulbp6 antibodies Active 29-Apr-2022
EP-4514383-A1 Antigen binding proteins Pending 29-Apr-2022 C07K16/2833
To view 23andMe’s complete patent history, request access »

23andMe Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

23andMe Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Investments & Acquisitions (4)

23andMe’s most recent deal was a Merger/Acquisition with Lemonaid Health for . The deal was made on 01-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lemonaid Health 01-Nov-2021 Merger/Acquisition Other Healthcare Services
Orchid 07-Apr-2021 Seed Round Other Healthcare Technology Systems
Doctor On Demand 20-Jul-2015 Early Stage VC Other Healthcare Services
CureTogether 10-Jul-2012 Merger/Acquisition Other Healthcare Services
To view 23andMe’s complete investments and acquisitions history, request access »

23andMe ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

21.38 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view 23andMe’s complete esg history, request access »

23andMe Exits (1)

23andMe’s most recent exit was on 20-Jul-2015 from Doctor On Demand. The exit was categorized as with 14 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Doctor On Demand 20-Jul-2015 Completed
  • 14 buyers
To view 23andMe’s complete exits history, request access »

23andMe Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Lemonaid Health San Francisco, CA 2013

23andMe FAQs

  • When was 23andMe founded?

    23andMe was founded in 2006.

  • Where is 23andMe headquartered?

    23andMe is headquartered in Sunnyvale, CA.

  • What is the size of 23andMe?

    23andMe has 709 total employees.

  • What industry is 23andMe in?

    23andMe’s primary industry is Laboratory Services (Healthcare).

  • Is 23andMe a private or public company?

    23andMe is a Public company.

  • What is 23andMe’s stock symbol?

    The ticker symbol for 23andMe is MEHCQ.

  • What is the current stock price of 23andMe?

    As of 22-Apr-2025 the stock price of 23andMe is $1.27.

  • What is the current market cap of 23andMe?

    The current market capitalization of 23andMe is $34.1M.

  • What is 23andMe’s current revenue?

    The trailing twelve month revenue for 23andMe is $209M.

  • Who are 23andMe’s competitors?

    Qiagen, Illumina, Personalis, Promethease, and OmeCare are some of the 9 competitors of 23andMe.

  • What is 23andMe’s annual earnings per share (EPS)?

    23andMe’s EPS for 12 months was -$15.70.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »